论文部分内容阅读
以往临床上对于失血性休克的救治,普遍采用输注全血及等渗液体,而高渗液体则应用极少且用量有限。近年来,一种具有自主知识产权的高渗液体——高渗氯化钠羟乙基淀粉40注射液(HH40),已获得国家新药证书和生产批文并应用于临床。现着重对其研究过程和应用特点综述如下。1 HH40的相关研究输液和输血是战伤救治和平时急救的重要组成部分,其中将输注等渗液体作为治疗低血容量患者的标准疗法,一直被业内倡导和使用至今~[1-2]。虽然等渗液
In the past clinically for the treatment of hemorrhagic shock, universal infusion of whole blood and isotonic liquid, while the hypertonic liquid is rarely used and the amount is limited. In recent years, a hypertonic liquid with independent intellectual property rights - hypertonic sodium chloride hydroxyethyl starch 40 injection (HH40), has obtained the national drug certificate and production approval and applied to clinical. Now it focuses on its research process and application features are summarized as follows. 1 HH40 related research Infusion and blood transfusions are important components of first aid for war injuries and emergency treatment. Among them, infusion of isotonic liquid as a standard treatment for patients with hypovolemia has been advocated and used in the industry up till now. . Although isotonic solution